Visual Abstract (IMAGE) Providence Health & Services Caption Transplant recipients from SARS-CoV-2 NAT+ donors have 30-day graft and patient survival similar to NAT- donors. DTAC review finds zero transmissions after lower respiratory tract testing policy. Credit Jason Goldman, M.D. Usage Restrictions None License Licensed content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.